Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,011 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
van Geel JJL, Boers J, Elias SG, Glaudemans AWJM, de Vries EFJ, Hospers GAP, van Kruchten M, Kuip EJM, Jager A, Menke-van der Houven van Oordt WC, van der Vegt B, de Vries EGE, Schröder CP; IMPACT-Metastatic Breast Consortium. van Geel JJL, et al. Among authors: jager a. J Clin Oncol. 2022 Nov 1;40(31):3642-3652. doi: 10.1200/JCO.22.00400. Epub 2022 May 18. J Clin Oncol. 2022. PMID: 35584346
Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N, Sieuwerts AM, Kraan J, Van NM, Onstenk W, Vitale SR, van der Vlugt-Daane M, Dirix LY, Brouwer A, Hamberg P, de Jongh FE, Jager A, Seynaeve CM, Jansen MPHM, Foekens JA, Martens JWM, Sleijfer S. Beije N, et al. Among authors: jager a. Mol Oncol. 2018 Jan;12(1):48-57. doi: 10.1002/1878-0261.12147. Epub 2017 Nov 17. Mol Oncol. 2018. PMID: 29063679 Free PMC article.
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, Menke-van der Houven van Oordt CW, Verheul HM, van Herpen CML, Jager A, Oosting SF, de Vries EGE, Schröder CP. van Es SC, et al. Among authors: jager a. Am J Surg Pathol. 2019 Oct;43(10):1355-1360. doi: 10.1097/PAS.0000000000001321. Am J Surg Pathol. 2019. PMID: 31283631
High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial.
Steenbruggen TG, Steggink LC, Seynaeve CM, van der Hoeven JJM, Hooning MJ, Jager A, Konings IR, Kroep JR, Smit WM, Tjan-Heijnen VCG, van der Wall E, Bins AD, Linn SC, Schaapveld M, Jacobse JN, van Leeuwen FE, Schröder CP, van Tinteren H, de Vries EGE, Sonke GS, Gietema JA. Steenbruggen TG, et al. Among authors: jager a. JAMA Oncol. 2020 Apr 1;6(4):528-534. doi: 10.1001/jamaoncol.2019.6276. JAMA Oncol. 2020. PMID: 31999296 Free PMC article. Clinical Trial.
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging.
Jager A, de Vries EGE, der Houven van Oordt CWM, Neven P, Venema CM, Glaudemans AWJM, Wang Y, Bagley RG, Conlan MG, Aftimos P. Jager A, et al. Breast Cancer Res. 2020 Sep 11;22(1):97. doi: 10.1186/s13058-020-01333-3. Breast Cancer Res. 2020. PMID: 32912274 Free PMC article. Clinical Trial.
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
Vliek SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, Dezentje VO, Jager A, Hokken JWE, Putter H, van der Velden AWG, Hendriks MP, Bakker SD, van Riet YEA, Tjan-Heijnen VCG, Portielje JEA, Kroep JR, Nortier JWR, van de Velde CJH, Linn SC. Vliek SB, et al. Among authors: jager a. J Clin Oncol. 2022 Sep 1;40(25):2934-2945. doi: 10.1200/JCO.21.00311. Epub 2022 Apr 20. J Clin Oncol. 2022. PMID: 35442755 Clinical Trial.
Changes in survival in de novo metastatic cancer in an era of new medicines.
Luyendijk M, Visser O, Blommestein HM, de Hingh IHJT, Hoebers FJP, Jager A, Sonke GS, de Vries EGE, Uyl-de Groot CA, Siesling S. Luyendijk M, et al. Among authors: jager a. J Natl Cancer Inst. 2023 Jun 8;115(6):628-635. doi: 10.1093/jnci/djad020. J Natl Cancer Inst. 2023. PMID: 36978244 Free PMC article.
1,011 results